Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (231-240 of 352) with videos related to

Pageof 36
Sort By:
Gut|January 7, 2011
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialWalter Reinisch, William J Sandborn, Daniel W Hommes, et al.
Journal of Crohn'S & Colitis|September 10, 2022
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPablo A Olivera, Juan S Lasa, Ignacio Zubiaurre, et al.
Gut|June 17, 2010
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialWalter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch, et al.
Inflammatory Bowel Diseases|February 8, 2013
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levelsSieglinde Angelberger, Elke Schaeffeler, Alexander Teml, et al.
Journal of Crohn'S & Colitis|June 20, 2018
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance ExtensionWalter Reinisch, Peter R Gibson, William J Sandborn, et al.
Journal of Crohn'S & Colitis|March 27, 2026
Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's diseasePaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
The American Journal of Gastroenterology|August 27, 2014
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3Jean-Frederic Colombel, William J Sandborn, Subrata Ghosh, et al.
Journal of Crohn'S & Colitis|April 1, 2025
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitisWalter Reinisch, Edward V Loftus, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisStephen Hanauer, Remo Panaccione, Silvio Danese, et al.
Inflammatory Bowel Diseases|October 9, 2018
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1Walter Reinisch, Brian Bressler, Rebecca Curtis, et al.
Pageof 36

Showing results (231-240 of 352) with videos related to

Sort By:
Pageof 36
Gut|January 7, 2011
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialWalter Reinisch, William J Sandborn, Daniel W Hommes, et al.
Journal of Crohn'S & Colitis|September 10, 2022
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPablo A Olivera, Juan S Lasa, Ignacio Zubiaurre, et al.
Gut|June 17, 2010
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialWalter Reinisch, Sieglinde Angelberger, Wolfgang Petritsch, et al.
Inflammatory Bowel Diseases|February 8, 2013
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levelsSieglinde Angelberger, Elke Schaeffeler, Alexander Teml, et al.
Journal of Crohn'S & Colitis|June 20, 2018
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance ExtensionWalter Reinisch, Peter R Gibson, William J Sandborn, et al.
Journal of Crohn'S & Colitis|March 27, 2026
Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's diseasePaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
The American Journal of Gastroenterology|August 27, 2014
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3Jean-Frederic Colombel, William J Sandborn, Subrata Ghosh, et al.
Journal of Crohn'S & Colitis|April 1, 2025
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitisWalter Reinisch, Edward V Loftus, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisStephen Hanauer, Remo Panaccione, Silvio Danese, et al.
Inflammatory Bowel Diseases|October 9, 2018
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1Walter Reinisch, Brian Bressler, Rebecca Curtis, et al.
Pageof 36